Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229329 | 0.85 | NPC1 (1.00) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL31560044 | 0.85 | NPC1 (1.00) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL9394256 | 0.85 | NPC1 (1.00) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL229328 | 0.85 | NPC1 (1.00) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL427375 | 0.85 | NPC1 (0.61) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL721181 | 0.80 | MEN1 (0.79) | RAB9AMEN1NPC1KMT2AATM | |
| Methyl Alcohol SCHEMBL28478479 | 0.80 | NPC1 (0.89) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL721182 | 0.80 | MEN1 (0.79) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL15535704 | 0.79 | NPC1 (0.48) | RAB9AMEN1NPC1KMT2AATM | |
| SCHEMBL22684051 | 0.79 | NPC1 (0.48) | RAB9AMEN1NPC1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 865 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| CN-108558932-B | Bis (2-pyridyl) methyl-substituted aminophenoxy magnesium complex and preparation method and application thereof | 华东理工大学 | 2022-10-25 | — | — | CN | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| CN-111362838-A | Urea group-containing diimine palladium catalyst, ligand thereof and application thereof in olefin polymerization | 中国科学技术大学 | 2020-07-03 | — | — | CN | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2177522-B1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2013-09-04 | — | — | EP | claimed |
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | claimed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | claimed |
| EP-1311513-B1 | CATALYSTS | BOREALIS TECH OY (FI) | 2004-10-06 | — | — | EP | claimed |
| EP-0707564-B1 | DIFLUORO STATONE ANALOGS | MERRELL PHARMA INC (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0276825-B1 | 4 (3H)-QUINAZOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-09-09 | — | — | EP | claimed |
| US-5008266-A | Antiulcer agent | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-04-16 | — | — | US | claimed |
| EP-0276825-A1 | 4 (3H)-Quinazolinone derivatives, processes for their preparation and pharmaceutical compositions | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1988-08-03 | — | — | EP | claimed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-111556872-B | Synthesis of borate derivatives and uses thereof | 梅琳塔治疗公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-1988002750-A1 | 1,4-DIHYDROPYRIDINE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-04-21 | — | — | WO | disclosed |
| EP-0205511-A1 | NEW PIPERAZINE DERIVATIVES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| WO-1986003748-A1 | NEW PIPERAZINE DERIVATIVES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT M (DE) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | RAB9A 3139/4885MEN1 3249/4885NPC1 1287/4885 |
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | RAB9A 790/4885MEN1 4343/4885NPC1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.